A Phase 4 interventional study of GLIMEPIRIDE + METFORMIN in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Kazakhstan. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-31.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.
Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 3 that started in 2010, is one of 24 in phase 4, and was the 22nd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 19 · Phase 4 24
First in 2000; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 169 across the 52 interventional studies. Of the 45 that completed or were terminated, 12 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 52 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 125th largest by enrollment of the 178 interventional ones that give a count, is one of 14 that started in 2010, is one of 75 in phase 4, and was the 89th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
Drug: GLIMEPIRIDE + METFORMIN
Drug pages: Glimepiride · Metformin
Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
Glycolysated Haemoglobin (HbA1c)
Time frame: From baseline to Month 4
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
Time frame: Month 4
Evolution of Fasting Plasma Glucose (FPG)
Time frame: From baseline to Months 4
Post Prandial Plasma Glucose (PPPG)
Time frame: Month 4
Number of patients for each start dose
Time frame: At baseline
Number of patients with different final doses
Time frame: Month 4
Rate of Symptomatic Hypoglycemia
Time frame: During treatment period (4 months)
Change in Weight
Time frame: Month 4
The record gives a start of May 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glimepiride · Metformin